PGPablo Gabriel-Medina

Pablo Gabriel-Medina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pablo Gabriel-Medina has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Calculation of reference intervals using an indirect approach from laboratory database

    by Victor Martin-Riera, Pablo Gabriel-Medina, Albert Blanco-Grau, Gonzalo Gonzalez-Silva, Yolanda Villena, Andrea Caballero-Garralda, Lydia Peris-Serra, Sarai Garriga Edo, Clara Sanz Gea, Fernando Moreno, et al.

    Objectives: The establishment of reference intervals (RIs) for biochemical parameters is crucial for the accurate interpretation of laboratory test results and clinical decision-making. This study aims to evaluate the feasibility of determining RIs using an indirect approach, which analyzes routine clinical samples instead of recruiting healthy individuals, thus leveraging large datasets while applying strict statistical criteria to exclude pathological values. Methods: This is a prospective study in which patients fulfilling inclusion criteria were recruited from the routine primary care to achieve a high proportion of healthy individuals. Biochemical magnitudes as creatinine, esterified bilirubin, ferritin, and transferrin were analyzed. A patient exclusion protocol was implemented to minimize results suggestive of pathology but ensuring a sufficient sample size for the calculation of new RIs. The new ones were compared with the RIs used in the laboratory, provided by the manufacturer. Results: The comparison between the newly calculated RIs and the existing laboratory RIs did not reveal statistically significant differences. The indirect approach provided robust RIs while maintaining data quality and a sufficient sample size. Conclusions: The findings support the effectiveness of this indirect approach for RI determination, provided that rigorous data quality standards and adequate sample sizes are maintained. The adoption of these RIs in clinical practice could enhance diagnostic accuracy and optimize healthcare resource utilization.


  • Open Access

    Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study

    by Jesús Rivera-Esteban, Alba Jiménez-Masip, Sergio Muñoz-Martínez, Salvador Augustin, Rafael A. Guerrero, Pablo Gabriel-Medina, Roser Ferrer-Costa, Francisco Rodríguez-Frías, Elisabet Turu, Andrés Marco, et al.

    Background and Aims: The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of this syndrome. We aimed to investigate the prevalence and risk factors of MASLD and MASLD-associated liver fibrosis in the penitentiary population in Catalonia, Spain. Method: A cross-sectional observational study involving eight penitentiary centers. Participants had at least one metabolic disorder and were at a closed-regimen penitentiary. Individuals with concomitant liver diseases and/or alcohol risk consumption were excluded. Significant fibrosis and MASLD were defined as liver stiffness ≥8 kPa and a controlled attenuation parameter ≥275 dB/m by vibration-controlled transient elastography (VCTE), respectively. After exclusions, metabolic inmates with VCTE were analyzed. Logistic regression analysis was performed to identify predictors of MASLD and MASLD-associated significant fibrosis. Results: Out of the 4338 inmates studied, 1290 (29.7%) had metabolic disorders, and 646 (14.9%) underwent VCTE. The mean age was 48.0 years (SD 12.1), and 89.5% were male. MASLD prevalence was 33.9%. Significant fibrosis and MASLD-associated significant fibrosis were found in 16.4% and 9.4% of inmates, respectively. In the multivariate analysis, T2D, waist circumference, MetS, and higher ALT values were identified as independent risk factors for MASLD and MASLD-associated significant fibrosis amongst the prison population. Conclusions: Metabolic disorders including MASLD are highly prevalent among inmates. The prevalence of significant fibrosis seems notably higher than that of the general population, underscoring the need for targeted screening programs and therapeutic interventions in the incarcerated population.


  • Open Access

    Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level

    by Pablo Gabriel-Medina, Roser Ferrer-Costa, Andreea Ciudin, Salvador Augustin, Jesus Rivera-Esteban, J. M. Pericàs, D. M. Selva, Francisco Rodriguez-Frias

    Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, and liver fibrosis is the strongest predictor of morbimortality. We aimed to assess the performance of a sequential algorithm encompassing the Fibrosis 4 (FIB-4) and Enhanced Liver Fibrosis (ELF) scores for identifying patients at risk of advanced fibrosis. This cross-sectional study included one hospital-based cohort with biopsy-proven NAFLD (n = 140) and two primary care cohorts from different clinical settings: Type 2 Diabetes (T2D) follow-up (n = 141) and chronic liver disease (CLD) initial study (n = 138). Logistic regression analysis was performed to assess liver fibrosis diagnosis models based on FIB-4 and ELF biomarkers. The sequential algorithm retrieved the following accuracy parameters in predicting stages F3–4 in the biopsy-confirmed cohort: sensitivity (85%), specificity (73%), negative predictive value (79%) and positive predictive value (81%). In both T2D and CLD cohorts, a total of 28% of patients were classified as stages F3–4. Furthermore, of all F3–4 classified patients in the T2D cohort, 80% had a diagnosis of liver disease and 44% were referred to secondary care. Likewise, of all F3–4 classified patients in the CLD cohort, 71% had a diagnosis of liver disease and 44% were referred to secondary care. These results suggest the potential utility of this algorithm as a liver fibrosis stratifying tool in primary care, where updating referral protocols to detect high-risk F3–4 is needed. FIB-4 and ELF sequential measurement is an efficient strategy to prioritize patients with high risk of F3–4 in populations with metabolic risk factors.


  • Utility of the Enhanced Liver Fibrosis score as a blood biomarker of pulmonary fibrosis secondary to SARS-CoV-2 pneumonia

    by Alexa Núñez, Cristina Aljama, Cristina Esquinas, Gerard Orriols, Pablo Gabriel-Medina, Georgina Farago, Galo Granados, Francisco Rodriguez-Frias, Mònica Pons, Marc Miravitlles, et al.


  • Open Access

    Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients

    by Emily Toscano-Guerra, Mónica Martínez Gallo, Iria Arrese-Muñoz, Anna Giné, Noelia Díaz, Pablo Gabriel-Medina, Mar Riveiro-Barciela, Moisés Labrador-Horrillo, Fernando Martinez-Valle, Manuel Hernández-González, et al.

    Infection with SARS-CoV-2 portends a broad range of outcomes, from a majority of asymptomatic cases or mild clinical courses to a lethal disease. Robust correlates of severe COVID-19 include old age, male sex, poverty and co-morbidities such as obesity, diabetes or cardiovascular disease. A precise knowledge is still lacking of the molecular and biological mechanisms that may explain the association of severe disease with male sex. Here, we show that testosterone trajectories are highly accurate individual predictors (AUC of ROC = 0.928, p < 0.0001) of survival in male COVID-19 patients. Longitudinal determinations of blood levels of luteinizing hormone (LH) and androstenedione suggest an early modest inhibition of the central LH-androgen biosynthesis axis in a majority of patients, followed by either full recovery in survivors or a peripheral failure in lethal cases. Moreover, failure to reinstate physiological testosterone levels was associated with evidence of impaired T helper differentiation and decrease of non-classical monocytes. The strong association of recovery or failure to reinstate testosterone levels with survival or death from COVID-19 in male patients is suggestive of a significant role of testosterone status in the immune responses to COVID-19.